<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645125</url>
  </required_header>
  <id_info>
    <org_study_id>M02-567</org_study_id>
    <nct_id>NCT00645125</nct_id>
  </id_info>
  <brief_title>A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications</brief_title>
  <official_title>A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To compare the taste and smell acceptability scores of cefdinir (Omnicef) versus amoxicillin
      oral antibiotic suspension medications in pediatric subjects. It is designed to determine if
      Omnicef or amoxicillin is preferred to the other with regard to taste or smell.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary Purpose for the study is &quot;Other&quot;. Per ClinicalTrials.gov, more information
      regarding the primary purpose is described here; the primary purpose for the study is to
      determine whether cefdinir possesses preferred taste and smell characteristics when compared
      to amoxicillin, a pediatric taste test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Taste and smell acceptability assessment</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events assessment</measure>
    <time_frame>72 hours with follow-up to a satisfactory conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medications</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any clinically abnormal observations</measure>
    <time_frame>2 hours with follow-up to a satisfactory conclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefdinir (Omnicef)</intervention_name>
    <description>2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ABT-198</other_name>
    <other_name>Omnicef</other_name>
    <other_name>cefdinir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
    <description>2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male child age 4 through 8 years in good general health.

          -  Minimum weight of 16.3 kg (36 lb).

          -  Willing to comply with appropriate instructions provided to complete the study.

          -  Written informed consent from parent/legal guardian.

        Exclusion Criteria:

          -  Current medical condition, that in the opinion of the Investigator or designee, could
             interfere with the ability to discriminate taste (e.g., common cold, sinus infection,
             bronchial infection, etc.).

          -  History of allergic reaction to cefdinir, prescription (e.g. penicillins or
             cephalosporins) and/or OTC medications, and/or food products.

          -  History of significant medical condition (e.g., GI disorders, hematological or
             bleeding disorders, renal or hepatic diseases).

          -  Use of any oral medication, vitamins or herbal supplements within 6 hours prior to
             tasting.

          -  Temperature &gt; than 99.2Â°F.

          -  Participation in a clinical or marketing research study within the past 3 months.

          -  Sibling of another subject on the study, or living in the same household as another
             subject that has participated in a clinical or marketing research study within the
             past 3 months.

          -  Family member or close friend employed by an advertising agency, market research
             company and/or a company that processes or manufacturers medical or health care
             products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>March 26, 2008</last_update_submitted>
  <last_update_submitted_qc>March 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Angela M Nilius, PhD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>pediatric taste test</keyword>
  <keyword>antibiotic taste test</keyword>
  <keyword>cefdinir</keyword>
  <keyword>amoxicillin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Cefdinir</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

